Vaishali Pharma's Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- Vaishali Pharma Ltd reported a 25.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were down by 27.3% QoQ and - - YoY.
- The net profit increased 10.9% QoQ and - - YoY.
- The earnings per share (EPS) of Vaishali Pharma Ltd stood at 0.1 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 25.54 | 34.29 | 0.00 | -25.5% | - |
Total Expenses | 23.73 | 32.63 | 0.00 | -27.3% | - |
Profit Before Tax | 1.82 | 1.66 | - | 9.6% | NaN% |
Tax | 0.51 | 0.47 | 0.00 | 8.5% | - |
Profit After Tax | 1.32 | 1.19 | 0.00 | 10.9% | - |
Earnings Per Share | 0.10 | 0.09 | 0.00 | 11.1% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Vaishali Pharma Ltd is a company engaged in the pharmaceutical industry. The company is known for its range of pharmaceutical products which may include tablets, capsules, injections, and other medical formulations. As a player in the healthcare sector, the company is positioned in an industry that is crucial for public health and wellness. However, specific recent developments or changes in the company’s operations, product lines, or strategic direction are not available in the provided data.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Vaishali Pharma Ltd reported a total income of ₹25.54 crores. This figure represents a decrease compared to the second quarter of fiscal year 2026 (Q2FY26), where the total income was ₹34.29 crores. The quarter-over-quarter (QoQ) change indicates a decline of 25.5%. Compared to the same quarter in the previous fiscal year (Q3FY25), there is no available data to provide insight into year-over-year (YoY) performance.
Profitability
Vaishali Pharma Ltd's profitability metrics show that the company generated a profit before tax of ₹1.82 crores in Q3FY26, improving from ₹1.66 crores in Q2FY26, reflecting a QoQ increase of 9.6%. The profit after tax for Q3FY26 was ₹1.32 crores, which is an increase from ₹1.19 crores in the previous quarter, showing a QoQ growth of 10.9%. The earnings per share (EPS) rose to ₹0.10 from ₹0.09 in Q2FY26, marking an 11.1% increase on a quarterly basis. Year-over-year figures for these profitability metrics were not available for analysis.
Operating Metrics
The financial data indicates that the total expenses for Vaishali Pharma Ltd in Q3FY26 were ₹23.73 crores, down from ₹32.63 crores in Q2FY26, which translates to a 27.3% decrease QoQ. Tax expenses also saw a modest increase from ₹0.47 crores in Q2FY26 to ₹0.51 crores in Q3FY26, registering an 8.5% QoQ rise. The absence of data for Q3FY25 means year-over-year comparisons for operating metrics are not available. No additional operating metrics, such as key financial ratios, could be derived from the provided data.